Swedish university hospital contributing clinical data, patient cohorts, and real-world evidence to European cardiovascular, oncology, and regulatory research.
Region Uppsala operates Akademiska University Hospital, one of Sweden's largest teaching hospitals, and serves as a clinical research partner in European health projects. Their H2020 participation spans cardiovascular medicine, oncology, pharmacovigilance in pregnancy, and medical device regulation. They contribute real-world clinical data, patient cohorts, and hospital pharmacy expertise to multinational research consortia. Their work bridges the gap between clinical practice and evidence generation, particularly in areas where real-world data is needed to complement clinical trials.
BigData Heart focused on heart failure and atrial fibrillation analytics; RITA-MI 2 is a phase 2 clinical trial for myocardial infarction treatment; OPTIMA applies AI to cardiovascular outcomes.
BigData Heart, OPTIMA, and ConcePTION all rely on real-world data collection, big data analysis, and predictive modelling from clinical practice.
CORE-MD addresses regulatory science for high-risk medical devices across cardiology, orthopaedics, and diabetes.
ConcePTION builds pharmacovigilance ecosystems for monitoring medication safety during pregnancy and lactation.
RealHOPE explores in-use handling of protein drugs with printed electronic tags, stability protocols, and pharmacy QC instruments.
OPTIMA applies artificial intelligence and real-world evidence to optimize treatment for patients with solid tumours, their largest single grant at EUR 483,000.
In their earlier H2020 period (2016–2019), Region Uppsala focused on cardiovascular disease fundamentals — heart failure, atrial fibrillation, and acute coronary syndrome — alongside pregnancy pharmacovigilance and pain self-management. From 2021 onward, their portfolio shifted decisively toward regulatory science, AI-driven treatment optimization, drug repurposing, and medical device evidence standards. This evolution shows a move from contributing clinical data to disease-specific projects toward shaping how evidence is generated and regulated across therapeutic areas.
Region Uppsala is positioning itself at the intersection of clinical practice and regulatory evidence generation, making them an increasingly valuable partner for projects that need real-world hospital data to validate AI tools, devices, or treatment protocols.
Region Uppsala operates exclusively as a consortium participant or third party — they have never coordinated an H2020 project, which is typical for hospital-based public bodies that contribute clinical infrastructure rather than lead research agendas. With 181 unique partners across 26 countries, they are a well-connected node in European health research networks. Their consistent participant role and broad partner base suggest they are a reliable, low-friction clinical site that consortia seek out for real-world data access and patient recruitment.
With 181 unique consortium partners spanning 26 countries, Region Uppsala has a remarkably wide European network for an organization with only 8 projects — reflecting participation in large, multi-site clinical consortia. Their connections are spread across the EU with no single geographic concentration.
Region Uppsala brings something most academic partners cannot: direct access to a major Swedish university hospital's clinical operations, patient records, and pharmacy infrastructure. Their recent projects show they are not just a data provider but are actively involved in shaping how evidence standards and AI tools are validated in real clinical settings. For consortium builders, they offer a credible Nordic clinical site with strong regulatory awareness and experience handling both traditional and biologic drugs.
